3-Amino-2,3,6-trideoxy-L-arabino-hexose

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Amino-2,3,6-trideoxy-L-arabino-hexose
• 英文别名: (3R,4S,5S)-3-amino-4,5-dihydroxyhexanal
• 化学式: C₆H₁₃NO₃
• 分子量: 147.17
• InChiKey: WPJRFCZKZXBUNI-KVQBGUIXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] AMPHETAMINE PRODRUGS<br/>[FR] PRO-MÉDICAMENTS À BASE D'AMPHÉTAMINES
  申请人：SHIRE AG

  公开号：WO2014002039A1

  公开（公告）日：2014-01-03

  The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.

  本发明涉及提供苯丙胺结肠释放的苯丙胺前药。
• GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY
  申请人：Rafai Far Adel

  公开号：US20120149632A1

  公开（公告）日：2012-06-14

  The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention and/or the treatment of bacterial infections.

  这项发明涉及具有与母体糖肽或脂质糖肽抗生素相比具有改变的电离状态的糖肽和脂质糖肽抗生素衍生物，并且具有在生理条件下能够再生为母体糖肽或脂质糖肽抗生素的能力。这些化合物可用作预防和/或治疗细菌感染的抗生素。
• [EN] POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES CONTENANT DES GROUPES DISULFURE
  申请人：SOLSTICE BIOLOG LTD

  公开号：WO2015069932A1

  公开（公告）日：2015-05-14

  The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

  该发明涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）包含靠近二硫键的一个或多个臃肿基团。该发明还涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分（i）连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）在二硫键和核苷酸桥连基团或末端基团的磷原子之间的链中至少包含4个原子；并且该链不包含磷酸酯、酰胺、酯或烯基烃。该发明还涉及使用该发明的聚核苷酸构造将聚核苷酸传递到细胞的方法。
• Click chemistry-derived cyclic peptidomimetics as integrin markers
  申请人：Kolb Hartmuth C.

  公开号：US20080213175A1

  公开（公告）日：2008-09-04

  The present application is directed to radiolabeled cyclic peptidomimetics, pharmaceutical compositions comprising radiolabeled cyclic peptidomimetics, and methods of using the radiolabeled cyclic peptidomimetics. Such peptidomimetics can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

  本申请涉及放射性标记的环状肽类似物，包括放射性标记的环状肽类似物的药物组合物，以及使用这些放射性标记的环状肽类似物的方法。这些肽类似物可用于影像研究，如正电子发射断层扫描（PET）或单光子发射计算机断层扫描（SPECT）。